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interpreted as having an ‘‘extremely large
effect on patient’s life’’ (Hongbo et al.,
2005). Imagine you want to evaluate the
effect of a treatment on the patient’s
quality of life that is extremely affected
by a dermatological disease (DLQI scores
between 21 and 30). You define success
when the score after the treatment is
between 11 and 20, because it is
considered clinically relevant. After
treatment, scores of one patient decrease
from 29 to 22, and scores of another
patient decrease from 22 to 18. Thus,
the treatment improved the quality of life
by seven points in case one, and by four
in case two. However, according to the
chosen cutoff score, only the latter would
be called ‘‘success,’’ although the
treatment effect was much lower.
Dichotomization blurs the sizes of
treatment effects, and it is therefore not
‘‘more clinically meaningful’’ (Nassar
et al., 2013, p 374).
Finally, we recommend not confusing
outcome measurements in RCTs with
clinical decision-making (Streiner, 2002).
RCTs are conducted to demonstrate
superiority, equivalence, or noninferiority
of treatment effects. As such, they must be
designed to maximize their internal
validity (Shadish et al., 2002)—that is, to
reduce bias and to increase the
probability of finding a difference when
one exists (i.e., power). This is best
achieved when the outcome variable
more closely matches the phenomenon
being studied. When that phenomenon is
itself a continuum, then its measurement
should be on a continuum. After—and
only after—the study has determined
whether there is a relationship between
the independent and dependent variables,
clinicians can then use this information to
make decisions regarding treatment.
Techniques, such as receiver operating
characteristic analysis, can be used to
determine optimal cutoff points (Streiner
and Cairney, 2007). As we mentioned
previously, these cutoff points can later be
changed in the light of new information,
but this can be done only if the outcome
had been measured on a continuum to
begin with, and cannot be done if the
outcome had been dichotomized a priori.
We completely agree with Nassar et al.
(2013) on the importance of primary
outcome constructions in dermatology
and other fields. The decision on
outcome variables should be based on
the objective of the RCT, on the validity
and reliability of the operationalization,
on the clinical relevance, and on avail-
able resources. Because parametric vari-
ables allow stronger inferences with
smaller sample sizes, they have advant-
ages over binary variables. If the outcome
in an RCT is measured on a continuum, it
should never be dichotomized.
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TO THE EDITOR
The mobilization and migration of epi-
dermal Langerhans cells (LCs) to
draining lymph nodes is dependent
upon receipt of (at least) two indepen-
dent cytokine signals; one provided by
IL-1b and the second by tumor necrosis
factor-a (TNF-a) (Cumberbatch et al.,
1997). Approximately 20–30% of epi-
dermal LCs are mobilized in response to
these signals (Griffiths et al., 2005).
Attention has focused recently on the
potential importance of LCs in un-
involved skin sites of patients withAccepted article preview online 28 June 2013; published online 25 July 2013
Abbreviations: FAE, fumaric acid ester; FCS, fetal calf serum; LC, Langerhans cell; PBS, phosphate-buffered
saline; PASI, psoriasis area severity index; TNF-a, tumor necrosis factor-a
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psoriasis (Cumberbatch et al., 2006;
Shaw et al., 2010). We have shown
previously that in subjects with early-
onset psoriasis (onset before 40 years of
age), LCs are refractory to all of those
stimuli (chemical allergen, IL-1b, and
TNF-a) that cause significant migra-
tion in healthy controls (Cumberbatch
et al., 2006). Further, we have shown
that impairment of LC migration in
early-onset psoriasis is likely a conse-
quence of the epidermal microenviron-
ment rather than an abnormality of LCs
themselves. However, the contribu-
tion of impaired LC migration to the
pathogenesis of psoriasis has not been
defined.
In the present investigation, we have
sought to determine whether effective
treatment of early-onset psoriasis, using
systemic therapies, can restore LC mobi-
lization. Examples of systemic thera-
pies include drugs that predominantly
act as T-cell antagonists (ciclosporin and
methotrexate; Menter and Griffiths,
2007), and biologics that inhibit cyto-
kines associated with the pathogenesis
of psoriasis, such as TNF-a (adalimumab
and etanercept) and IL-12/IL-23
(ustekinumab; Nestle et al., 2009).
Fumaric acid esters (FAEs) are an alter-
native systemic therapy for moderate-to-
severe psoriasis, although their precise
mechanism of action has yet to be
elucidated (Wain et al., 2010).
To facilitate a more searching exam-
ination of the potential role of compro-
mised LC mobility in psoriasis, and its
contribution to disease pathogenesis, we
have developed an ex vivo epidermal
explant model. This model is based on a
modification of assays that have primar-
ily monitored LC migration in explants
as a function of LCs accumulating in the
explant medium (Ratzinger et al., 2002;
de Gruijl et al., 2006; Bond et al.,
1999). Development of such a model
obviates recourse to intradermal injec-
tion of either IL-1b or TNF-a as has been
used previously (Cumberbatch et al.,
2006).
Patients with early-onset psoriasis
(n¼ 40; mean age 39.9±1.4 years; 15
female and 25 male) and healthy con-
trols (n¼6; mean age 24.3±2.4 years;
4 female and 2 male) were recruited
following provision of written informed
consent. The study was approved by the
Salford and Trafford Research Ethics
Committee (05/Q1404/249) and was
conducted according to the Declaration
of Helsinki. Individuals with early-onset
psoriasis were either on topical therapy
alone (untreated) or were recruited
because they had shown physician-
determined clinical improvement while
receiving one of the aforementioned
six systemic therapies. Inclusion criteria
for patients on topical therapy alone
included no use of systemic therapies
for at least 4 weeks, and for healthy
volunteers, no history of any skin dis-
ease. Clinical severity of individuals
with early-onset psoriasis ranged from
psoriasis area severity index (PASI)
scores of 0–25.7. For the individual
groups, PASI scores were as follows:
untreated: 0–25.7; methotrexate: 5–7.8;
ciclosporin: 0.5–9.5; etanercept: 6.2–
12.2; adalimumab: 2–5.3; ustekinumab:
0–8.5; and FAEs: 2.4–3.6.
Two, 6-mm diameter skin biopsies
were taken from sun-protected buttock
skin under 1% lidocaine local anesthe-
sia. For psoriasis patients, biopsies were
taken from normal-appearing clinically
uninvolved skin 45 cm from a plaque
of psoriasis. Biopsies were collected
into 10% fetal calf serum (FCS)/RPMI
media containing 2.5mg ml 1 ampho-
tericin B, 200mg ml 1 streptomycin
and 200 U ml1 penicillin (all from Life
Technologies, Paisley, UK), and epider-
mal sheets were prepared as described
previously (Cumberbatch et al., 2006).
In every experiment, one epidermal
sheet was processed immediately for
LC counting (T¼0); the remaining epi-
dermal sheet was floated on 500ml of
culture media (10% FCS/RPMI con-
taining 100mg ml1 streptomycin and
100 U ml1 penicillin) in 12-well
plates and incubated at 37 1C in a 5%
CO2 environment for 24 h (T¼24).
Following the 24-h incubation, epi-
dermal sheets were washed briefly in
phosphate-buffered saline (PBS), pro-
cessed for staining with a monoclonal
antibody specific for CD1a (clone NA1/
34; 10mg ml 1 in 0.1% bovine serum
albumin/PBS; Dako Ltd., Stockport, UK)
and assessed and counted as described
previously (Cumberbatch et al., 2006).
For each sample, 50 consecutive fields
in the central portion of the biopsy
were examined, and the results were
expressed as the mean number of cells
per mm2. Data are expressed either as
LC frequency at T¼ 0 and 24 for each
individual donor or with respect to the
percentage change in LC frequency at
T¼24 compared with baseline (paired
T¼0) data:
% Migration¼
T ¼0 LC mm2ð Þ
 T ¼24 LC mm2ð Þ
 
T ¼ 0 LC mm 2ð Þ 100
LC frequency (T¼0 versus T¼ 24)
data were analyzed by paired t-test,
and % migration data were analyzed
using one-way analysis of variance fol-
lowed by Dunnett’s multiple compa-
rison post hoc tests using the untreated
early-onset psoriasis patients as the
comparator. Po0.05 was chosen as
the threshold for statistical significance.
The historical data (Cumberbatch
et al., 2003, 2006) demonstrate that
although intradermal administration of
IL-1b to healthy volunteers induced
a significant decrease (n¼ 10; 19.7±
2.0%; Po0.05; Figure 1a) in LC fre-
quency, treatment of uninvolved skin
of early-onset psoriasis patients failed
to induce any LC migration (n¼ 7; 1.1±
0.5%; Figure 1b). An identical pattern
was recapitulated in the ex vivo epider-
mal explant model. LCs migrated spon-
taneously from all explants derived from
healthy controls after 24 h in culture
(n¼ 6; 19.8±3.7%; Po0.05; Figure 1c).
The release of factors in response to the
trauma of the biopsy procedure is thought
to drive the spontaneous migration of LCs
in the explant model (Ratzinger et al.,
2002). The extent of migration (approxi-
mately 20% of LCs) observed was similar
to that provoked by in vivo stimuli such
as IL-1b (Figure 1a). However, there
was no significant LC mobilization from
explants derived from uninvolved skin
of patients with psoriasis solely on topical
therapies (untreated; n¼ 5; 2.2±1.1%;
Figure 1d). Thus, to this extent, at least,
the explant model faithfully reflects the
in vivo differences observed between
normal subjects and those with early-
onset psoriasis with regard to cytokine-
(TNF-a or IL-1b) induced migration
(Cumberbatch et al., 2006).
To investigate the effect of systemic
therapies on LC migration, LC frequen-
cies at baseline (T¼0) and T¼ 24 from
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untreated individuals were compared
with healthy controls and patients
who had shown a clinical response
(reduction in PASI) to systemic therapy.
The overall patterns of responses are dis-
played as percentage migration of LCs
following 24 h incubation of epi-
dermal explants compared with baseline
T¼0 levels (Figure 1e). Given the rela-
tively low numbers for some groups, in
order to aid statistical analyses data
have been combined for those therapy
groups with a common mechanism
(the T-cell therapies, methotrexate and
ciclosporin, and the TNF-a inhibitors,
etanercept and adalimumab). Despite
inter-donor variability in all groups, it
is nevertheless apparent that, compared
with the untreated psoriasis group
(n¼ 16; 4.0±1.4%), there was signifi-
cant spontaneous migration of LCs in
explants taken from healthy donors
(19.8±3.7%; raw data previously illu-
strated in Figure 1c; Po0.05), and from
patients receiving systemic therapy
with TNF-a inhibitors (etanercept
(n¼ 6) and adalimumab (n¼2); 14.1±
2.9%; Po0.05), ustekinumab (n¼6;
14.0±3.8%; Po0.05) or FAEs (n¼4;
22.4±5.7%; Po0.05). In contrast, there
was little or no restoration of LC mobi-
lization observed in patients receiving
T-cell-targeted therapies (methotrexate
(n¼ 4) and ciclosporin (n¼3); 4.3±
2.0%) despite clinical improvement.
Collectively, these data indicate that
systemic treatment of psoriasis patients
with non-T-cell-targeted therapies is
associated with a significant restoration
of epidermal LC migration in un-
involved skin. Adalimumab and etaner-
cept are TNF-a inhibitors, whereas
ustekinumab targets the p40 subunit
common to IL-12 and IL-23. The
mechanism of action of FAEs has yet
to be elucidated fully, although one
study suggests that it may also target
IL-12/IL-23 signaling in psoriasis
(Ghoreschi et al., 2011). A previous
study reported restoration of epidermal
LC frequency in plaques of psoriasis that
preceded clinical response to treatment
with adalimumab (Gordon et al., 2005).
Our findings support the importance of
the regulatory role of LCs in psoriasis,
although we have not investigated their
function in involved plaques. In contrast,
we have shown that the predominantly
T-cell-targeted therapies failed to restore
LC migration despite effective clearance
of psoriasis. This observation is consis-
tent with a previous study that showed
that successful treatment of patients with
ciclosporin was not associated with an
increase in the frequency of LCs within
plaques compared with pretreatment
values (Gupta et al., 1989).
In summary, we have developed an
ex vivo epidermal explant model that
can be used to interrogate the mecha-
nisms underlying LC migration and
the effect of therapy on LC migration
in psoriasis. Furthermore, we have
shown that LC mobilization is restored
in patients on therapies that target key
cytokines in psoriasis pathogenesis and
hence cell signaling within the epi-
dermal environment. Although the influ-
ence of impaired LC mobilization on
the pathogenesis of psoriasis is presently
uncertain, a speculation is that the loss
of LC motility may have an important
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Figure 1. Explant model to investigate Langerhans cell (LC) migration in early-onset psoriasis: impact of
systemic therapies. Historical data (Cumberbatch et al., 2003; 2006) showing LC frequencies 2 h post
in vivo intradermal administration of 50 or 100 U IL-1b or saline control in: (a) healthy individuals
and (b) patients with early-onset psoriasis. LC frequencies assessed using the explant model for epidermal
sheets from (c) healthy individuals and (d) patients with psoriasis processed immediately (T¼0) and
at 24 h (T¼ 24). (e) Percentage LC migration in the explant model for untreated psoriasis patients,
healthy volunteers, and psoriasis patients on various treatments: TNF-a inhibitors (etanercept (m) and
adalimumab (’)), T-cell therapies (ciclosporin (.) and methotrexate (~)), fumaric acid esters (FAEs),
or ustekinumab. Each line/data point represents an individual donor (for ustekinumab, one patient
made two independent visits). Statistical analyses: paired t-test (a–d) or one-way analysis of variance
and Dunnett’s post hoc test (e). #Po0.05.
FL Shaw et al.
Treatment-Related Restoration of Langerhans
270 Journal of Investigative Dermatology (2014), Volume 134
impact on the ability of these cells to
sense the local antigenic microenviron-
ment and regulate cutaneous immune
responses. It is also not clear why
certain therapeutic interventions, but
not others, are associated with a restora-
tion of LC motility. It may be that anti-
TNF and anti-IL-12/23 therapies result in
a resetting of normal epidermal func-
tion, including LC mobilization. These
data demonstrate the utility of the
ex vivo explant model and provide
evidence that aberrant LC mobilization
is a function of the psoriatic process,
rather than a predisposing phenotype.
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Loss of IL36RN Function Does Not Confer Susceptibility
to Psoriasis Vulgaris
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TO THE EDITOR
Recessive mutations of the gene encod-
ing the interleukin-36 receptor antago-
nist (IL36RN) have been associated with
generalized pustular psoriasis, palmar-
plantar pustulosis, and acrodermatitis
continua of Hallopeau (Marrakchi
et al., 2011; Onoufriadis et al., 2011;
Setta-Kaffetzi et al., 2013). As patients
suffering from these pustular conditions
often present with concomitant psoriasis
vulgaris (PV), it has been proposed that
IL36RN deficiency may also contri-
bute to PV susceptibility (Marrakchi
et al., 2011). This hypothesis is sup-
ported by the observation that mice
lacking il36rn show exacerbated symp-
toms of imiquimod-induced psoriasiform
dermatitis and enhanced infiltration of
inflammatory cells in the dermis and
the epidermis (Tortola et al., 2012). The
elevated expression of IL-36 cytokines
in psoriatic skin (Carrier et al., 2011;
Johnston et al., 2011) is also consistent
with the notion that abnormal IL-36
signaling has an important role in the
establishment of cutaneous inflamma-
tion (Supplementary Figure 1 online).
On the basis of the above findings,
it has recently been suggested that
IL-36 blockade could be an innovativeAccepted article preview online 21 June 2013; published online 18 July 2013
Abbreviations: IL36RN, interleukin-36 receptor antagonist gene; PV, psoriasis vulgaris
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